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Glycogen Synthase Kinase-3 (GSK3) was originally reported as a key enzyme of glucose homeostasis
through regulation of the rate of glycogen synthesis. It has subsequently been found to influence most
cellular processes, including growth, differentiation and death, as part of its role in modulating response
to hormonal, nutritional and cellular stress stimuli. More than 100 protein targets for GSK3 have been
proposed although only a small fraction of these have been convincingly validated in physiological cell
systems. The effects of GSK3 phosphorylation on substrates include alteration of enzyme activity, protein
localisation, protein:protein interaction and protein stability. This latter form of regulation of GSK3 sub-
strates is the focus of this review. There is an ever-growing list of GSK3 substrates that upon phosphory-
lation are targeted to the beta-transducin repeat containing protein (b-TrCP), thereby allowing
ubiquitination of bound protein by cullin-1 and so initiating destruction at the proteasome. We propose
the existence of a GSK3-b-TrCP ‘destruction hit-list’ that allows co-ordinated removal (or stabilisation) of
a set of proteins with a common physiological purpose, through control of GSK3. We identify 29 proteins
where there is relatively strong evidence for regulation by a GSK3-b-TrCP axis and note common features
of regulation and pathophysiology. Furthermore, we assess the potential of pre-phosphorylation (prim-
ing) of these targets (normally a prerequisite for GSK3 recognition) to provide a second layer of regulation
delineated by the priming kinase that allows GSK3 to mark them for destruction. Finally, we discuss
whether this knowledge improves options for therapeutic intervention.
 2017 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
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Glycogen synthase kinase-3 (GSK3) is named after the first sub-
strate identified, glycogen synthase, and although it does modulate
glycogen synthesis rate in liver and muscle, it is now known to
influence many additional cellular processes; including cell prolif-
eration, cell differentiation, neuronal signaling, immune function,
inflammation, and nutrient sensing [1–3]. GSK3 is widely touted
as a potential therapeutic target for many chronic diseases. As
such, a better understanding of how GSK3 targets its substrates
in health and disease could provide a more disease-selective inter-
vention strategy.2. GSK3 biology
2.1. GSK3 regulation
There are two mammalian GSK3 genes (GSK3 a and GSK3 b)
which are >90% identical in their catalytic domain sequences and
which are expressed ubiquitously. GSK3 b deletion results in post-
natal lethality, with multiple developmental defects and loss of
hepatic function [4]. In contrast, GSK3 a null mice are viable and
relatively healthy, with defects in glucose metabolism [5]. Interest-
ingly, GSK3 a null mice have a shorter lifespan than controls and
are more prone to chronic age-related diseases [6]. Therefore
GSK3 a and GSK3 b isoforms contribute to different non-
redundant and vital aspects of healthy ageing in rodents.
GSK3 is central to multiple intracellular pathways including
those activated by Wnt/b-catenin, Sonic Hedgehog, Notch, growth
factor/RTK, and G protein-coupled receptor signals [7,8]. It is rela-
tively active in unstimulated cells and mostly regulated by
decreasing its activity [3].
There are several regulatory mechanisms which control GSK3
activity; a) phosphorylation of Ser21 in GSK3 a and the equivalent
residue in GSK3 b, Ser9 [9], which inhibits phosphorylation of
primed substrates [10], b) disruption of GSK3-containing protein
complexes such as the axin-APC complex [11], c) phosphorylation
of Thr390 of GSK3 b by p38MAPK which inhibits this isoform [12]
and d) acetylation [13]. In addition, phosphorylation of Tyr279 of
GSK3 a (and the equivalent Tyr216 of GSK3 b) is required for cat-
alytic activity [14], and although this residue is phosphorylated
during synthesis of GSK3, this specific modification may be dynam-
ically regulated in neurons [15]. The relative importance of each
mechanism to GSK3 regulation may vary from tissue to tissue,
and potentially in response to specific stimuli. In particular, growth
factors tend to regulate GSK3 through N-terminal phosphorylation
(although different kinases are used by different stimuli). Mean-
while the canonical Wnt signaling pathway disrupts the interac-
tion between GSK3 and Wnt-specific targets [16], without
regulating the N-terminal phosphorylation of GSK3 [17]. Therefore,
Wnt proteins and growth factors appear to regulate different pools
of GSK3 within cells [17] and, as such, these pathways regulate dif-
ferent GSK3 substrates [18]. This is important as changes in totalcellular GSK3 activity will not necessarily alter the phosphoryla-
tion status of every GSK3 substrate.
2.2. GSK3 substrate priming
The majority of GSK3 targets require prior phosphorylation (by
a distinct kinase) to generate a GSK3 consensus sequence (SX3or4S
(P), with the C-terminal serine phosphorylated) [17]. This is termed
priming and enhances phosphorylation of peptide substrates by
GSK3 more than 1000-fold. Priming provides opportunities for
physiological, pathophysiological or pharmacological manipula-
tion of specific groups of substrates primed by a common protein
kinase, independent of direct GSK3 regulation. That is, physiologi-
cal or pharmacological inhibition of a priming kinase could reduce
GSK3 phosphorylation of only those GSK3 substrates primed by
that kinase, even when GSK3 activity was high. The corollary of
this is that high GSK3 activity associated with disease does not
necessarily mean all GSK3 substrates will be hyperphosphorylated
(if priming of some substrates is limiting). Importantly priming of
different GSK3 substrates appears to rely on distinct priming
kinases. For example, CKI primes APC [19], b-catenin [20], Mdm2
[21], and VHL [22]; CDK5 primes CamKK b [23], CLASP2 [24],
CRMP1 [25], CRMP2 [25], Mef2D, and some sites on tau [26];
PKA primes ATP-citrate lyase [27], Ci-155 [28], CREB [29], GATA4
[30] and PP1 G-subunit [31]; ERK2 primes Bcl-3 [32], C/EBP b
[33], HSF1 [34], MafA, KRP (telokin) [35], and c-myc/L-myc [36];
DYRK primes eIF2B [37], NFAT [38], tau [26], and possibly CRMP4
[39] and NRF2 (HR unpublished data); and CKII primes glycogen
synthase [40], and probably protein phosphatase inhibitor-2 and
PTEN [3]. There are at least five additional kinases proposed to
act as priming enzymes (including SGK, DNA-PK and AMPK).
2.3. Physiology and pathophysiology
The first physiological role that was identified for GSK3 was reg-
ulation of glycogen synthesis and glucose metabolism, and this has
been studied in great detail for many years [41–45]. Genetic abla-
tion in mice has demonstrated a vital role for GSK3 b in tissue
development [4], while key roles in cell proliferation, cell differen-
tiation, control of microtubule structure, cell cycle progression, and
apoptosis, have all been proposed. The diverse range of substrates
identified to date would predict that GSK3 has an influence on vir-
tually every cellular process, although it remains to be established
how many of these proposed substrates are ‘bona fide’ physiolog-
ical or pathophysiological substrates [3].
Significant alterations in GSK3 activity have been reported in
several age-related human diseases including diabetes, cancer,
and Alzheimer’s disease (AD) (see Section 6). Partial deletion
(pharmacological or genetic) of GSK3 reduces the development
and/or severity of models of these diseases [46–48] implying a role
for GSK3 hyperactivation in their initiation/early progression [3].
As such, several pharmaceutical companies have developed selec-
tive, and potent, GSK3 inhibitor small molecules.
Fig. 1. Schematic comparison of two proteins which are targeted for degradation in a GSK3 and b-TrCP-dependent fashion. Pharmacological inhibition of GSK3 activity would
be predicted to lower recognition by b-TrCP, preventing ubiquitination by CUL1 and co-ordinated stabilization of both proteins. However there is scope for physiological and
pharmacological target specific regulation. 1) b-Catenin, but not NRF2, is present within a complex that permits regulation by Wnt signaling, hence GSK3 inhibition by Wnt
signaling would stabilize b-catenin but not NRF2, 2) the two proteins are primed by distinct protein kinases providing the possibility for enhancing or reducing GSK3
targeting through regulation of the priming kinase and 3) GSK3 may only phosphorylate one of the two serines in the NRF2 phosphodegron, and a distinct kinase may be
needed to fully engage b-TrCP and enhance degradation, while GSK3 is sufficient to complete the b-TrCP-binding motif in b-catenin.
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GSK3, the exception possibly being the AD tangle protein, tau
[49]. A better understanding of whether it is GSK3 regulation or
regulation of specific GSK3 substrates that is altered in human dis-
ease could allow a more targeted disease specific intervention. This
would likely be more effective and certainly safer than global GSK3
inhibition. For example, phosphorylation of substrates by GSK3
produces a wide range of effects on target function, including
altered enzyme activity, protein localization, and protein stability.
The list of human diseases associated with both GSK3 defects, and
dysregulated protein degradation or accumulation, continues to
grow. Therefore, it is likely that validation of the rapidly lengthen-
ing list of GSK3 substrates targeted for degradation may provide
insight into a mechanistic link between GSK3 and pathophysiology
of such diseases.
The remaining sectionswill investigate the hypothesis that GSK3
is a major regulator of protein stability. In particular we focus on
GSK3 substrates that share the same partner for targeting the sub-
strate to the proteasome, namely the SCF (SKP1, cullin-1, F-box pro-
tein) E3 ubiquitin ligase b-TrCP. Interestingly, b-TrCP binding of
proteins is enhanced by dual phosphorylation of the substrate, with
a similar spacing of the two phosphorylated residues to that gener-
ated by GSK3 phosphorylation of primed substrates (Fig. 1).3. The GSK3-b-TrCP axis
The ubiquitin proteasome system (UPS) is the predominant
route by which eukaryotic proteins are turned over in the cell,
and defects in the UPS have been implicated in a range of diseases
such as immune disorders, neurological disorders and cancer [50].3.1. Ubiquitination
Ubiquitin is a small (8.5 kDa) ubiquitously expressed protein,
encoded by four human genes (UBB, UBC, UBA52 and RPS27A).The covalent attachment of ubiquitin to a target protein (ubiquiti-
nation) most commonly results in its degradation by the
proteasome.
Ubiquitination involves three basic steps: 1) ATP-dependent
activation of ubiquitin, 2) conjugation of ubiquitin to an intermedi-
ary protein, and 3) ligation of the ubiquitin to the target protein.
These steps are performed by ubiquitin-activating enzymes (E1s),
ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s),
respectively. Importantly ubiquitination can involve attachment
of a single ubiquitin molecule (mono-ubiquitination) or the gener-
ation of a chain of linked ubiquitin molecules (poly-ubiquitination)
[51]. The first ubiquitin molecule is covalently bound (ligated)
through its C-terminal carboxylate group to a particular lysine resi-
due within the target protein, and the chain can then be elongated
by linking ubiquitin molecules to one of the seven lysine residues
(or the N-terminal methionine) of the previous ubiquitin molecule.
It is the polyubiquitination on specific lysines, mostly on Lys48 and
Lys29 of ubiquitin that leads to degradation of the target protein by
the proteasome [52]. Polyubiquitinations at other lysines, or
monoubiquitinations, do not normally lead to degradation, rather
they can contribute to the regulation of several other cellular pro-
cesses (including endocytic trafficking, inflammation and DNA
repair). This is because only the Lys48 and Lys29 linked polyubiq-
uitin tag can be recognized by the 26S proteasome leading to
unfolding of the target protein and ultimately degradation [52].
Some specificity to, and regulation of, this process is provided
by the existence of a large family of E3 ubiquitin ligases (>600
members), all with the ability to transfer ubiquitin to the protein
target [53]. The E3 ligases can be subdivided into three main
groups based on their characteristic domain and their mechanism
of action. Firstly, the Homologous to the E6AP carboxyl terminus
(HECT) family which form temporary bonds to ubiquitin, before
transferring it to the substrate protein. Secondly, the Really inter-
esting new gene (RING) family, which do not bind ubiquitin
directly, but serve as adaptors for ubiquitin transfer from the E2
enzymes [54]. Thirdly, the RING-between RING (RBR) family,
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including the intermediate binding of ubiquitin, as seen in the
HECT family.3.2. The SCF (SKP1, cullin-1, F-box protein) E3 ubiquitin ligase family
One of the best examples of the large family of RING E3 ligases
is provided by SCF containing complexes, of which there are 69
known in humans [54]. The SCF complex is made up of four com-
ponents; RBX1, cullin-1, S-phase-kinase-associated-protein 1
(SKP1) and an F-box protein (Fig. 1). Each of these proteins works
in concert and provides a unique function to the complex. The
RBX1 protein contains the Zinc-binding RING finger domain that
enables the transfer of ubiquitin from the E2 ligase to the lysine
residue on the target protein, and it also binds cullin-1. The
cullin-1 protein functions as a scaffold to link RBX1 to SKP1, while
the SKP1 protein brings the F-box protein into the complex. F-box
proteins vary in sequence outside their F-box domain and their
SKP1 binding site, and this variability provides some target speci-
ficity to the complex. This is usually mediated through carboxyl
terminal protein:protein interaction motifs, such as WD40 repeats
which have a b-propeller structure that recognizes phosphorylated
targets, and Leucine-rich repeats (LRR) which have a/b-repeat
structures and bind independently of target phosphorylation
[55,56].
b-Transducin repeat containing proteins (b-TrCP, b-TrCP1 and
b-TrCP2) are the best studied of the WD40 subfamily of F-box pro-
teins. b-TrCP proteins are responsible for the ubiquitination of a
wide range of critical proteins including; IjK phosphorylated IjB,
GSK3 phosphorylated b-catenin, cell cycle regulatory proteins
CDC25 and APC, and many more [57]. Substrates that are recog-
nized by b-TrCP proteins often contain a destruction motif,
DSGXXS, in which X represents any amino acid [57]. Phosphoryla-
tion of both serine residues in the motif enhances recognition by
b-TrCPs, and thus when phosphorylated, it is sometimes referred
to as a phosphodegron.
Misregulation of b-TrCP proteins, has been implicated in cancer
development and progression, mainly because it controls the
degradation of several tumour suppressor proteins [58]. Relatively
high levels of b-TrCP have been detected in cell lines derived from
human breast and prostate tumours, and also in breast prostate,
and gastric tumour, tissue samples from patients [59].3.3. Interaction between phosphorylation and ubiquitination
As mentioned above, b-TrCP targets often contain a destruction
motif, DSGXXS, and the phosphorylation of both of the serines in
this sequence greatly enhances the recognition by b-TrCP [60]. As
this sequence closely resembles the GSK3 target consensus,
(SX3or4S(P), with the C-terminal serine phosphorylated) it is per-
haps not surprising that so many GSK3 substrates are now
reported to be b-TrCP binding proteins (Table 1). One of the origi-
nal GSK3 targets, b-catenin, contains this sequence. It is primed by
CK1 for subsequent GSK3 phosphorylation, and this generates a
b-TrCP binding motif, thereby enhancing polyubiquitination and
degradation by the proteasome (Fig. 1). More recently, another
transcription factor, NRF2, was found to be regulated in a highly
similar fashion (Fig. 1). Indeed, it seems plausible that GSK3 and
b-TrCP co-ordinate the destruction of a wide range of proteins in
response to given cues. In the following section (and Table 1) we
detail the growing list of GSK3-b-TrCP regulated proteins. It is
worth noting that b-TrCP promotes the degradation of many pro-
teins that are not considered GSK3 substrates (eg IkB [61]), thus
the GSK3-b-TrCP axis may regulate only a selection of b-TrCP
targets.4. GSK3 substrate regulation
4.1. General
There are over 100 proposed substrates of GSK3 [3], and the
proportion of these reported to be degraded in response to GSK3
phosphorylation is growing rapidly ([18] and Table 1). Clearly
degradation is the ultimate regulatory mechanism, completely
removing all functions of the protein, and raises the interesting
possibility that the GSK3-b-TrCP axis is used to co-ordinate the
removal of specific sets of proteins in response to different envi-
ronmental cues. Equally, loss of control of this axis could underpin
the observed association of dysregulated GSK3 and its targets in
many age-related diseases.4.2. GSK3 and protein degradation
Table 1 lists substrates with compelling evidence that their
steady state protein level can be modulated through phosphory-
lation by GSK3, and subsequent ubiquitination by b-TrCP, or a
close homologue. Almost certainly this is not going to represent
the final comprehensive list. Indeed, Gumbiner and colleagues
performed an expression cloning screen in Xenopus eggs which
identified 35 novel proteins whose degradation/stability
appeared to be regulated by GSK3 inhibition. Of course, it is pos-
sible that GSK3 will co-operate with E3 ligases other than b-
TrCP, however it seems unlikely to be a coincidence that b-
TrCP and GSK3 share such a common recognition motif. That
said, there are a few examples of GSK3 targets which go on to
be degraded following ubiquitination by Fbw7, fbxl3, skp2 and
Smurf1 E3 ligases ([18]). It will be interesting to establish how
many of these other E3 ligases exhibit enhanced activity follow-
ing dual phosphorylation of the target, or whether the phospho-
rylated residues are not part of the recognition motif. Table 1
mostly focuses on targets where the residues phosphorylated
are known and/or the evidence linking GSK3 and b-TrCP activity
to degradation is strong. In theory, this table is a draft ‘GSK3-b-
TrCP target destruction hit-list’, where the cellular complement
of all of these proteins would be reduced by a b-TrCP mediated
process following enhanced GSK3 activity. Conversely, their pro-
tein levels are likely to increase following physiological or phar-
macological inhibition of GSK3. In reality of course, there will be
a number of factors determining whether the levels of all of
these proteins are regulated by GSK3-b-TrCP in a truly coordi-
nated fashion.
For example, the overall effect of the GSK3-proteasome
partnership will be dictated by the affinity for the substrate
(phosphorylation rate, steady state phosphorylation, binding to
b-TrCP). In addition, the stoichiometry of priming (and the speci-
fic priming pathway involved-see Section 5) along with the cellu-
lar substrate concentration will influence the proportion of
substrate that can be targeted for destruction (very abundant,
poorly primed substrates will be depleted very slowly). Each tar-
get may also exhibit distinct rates of dephosphorylation, while
the expression of target PPases may vary between cell types, or
with environmental cues. Finally, the cellular location of the sub-
strate, priming kinase, PPase and ubiquitination machinery may
vary with cell type (eg if phosphorylation occurs in a compart-
ment without b-TrCP or other proteasome factors). In this way,
one could envision several subgroups of GSK3-b-TrCP targets with
distinct rates of destruction dependent on the factors mentioned
above. It is likely though that pathophysiological disruption of the
GSK3 and/or b-TrCP pathways would produce a global induction
of all of the proteins in Table 1, potentially with deleterious
consequences to the cell/tissue.
Table 1
GSK3 substrates that are degraded after phosphorylation. Sequences given are human unless specified, the GSK3 phosphorylation sitexxx is given in bold and underlined, while the priming site is in bold.
Substrates GSK3 Phosphorylation site. Priming Site (Kinase) GSK3 target Sequence Ref.
Group 1-Substrates with the DSGX(X)S motif
Beta catenin (proto-oncogene) Ser33, Ser37 and Thr41 Ser45 (CK2) LDS33GIHSGATTTAPSL [11,20,63]
CHD1 (induces pro-tumourogenic
signaling)
Proposed as Ser24 and Ser54 Proposed as Ser28 and Ser58 DDS24GSASGS and SDS54GSESGS [65]
FGD1 (faciogenital dysplasia) FGD3 Ser283
Ser72
Ser287 (putative)
Ser76 (putative)
RDS283GIDSISS
RDS72GIDSPSS
[69,70]
Prolactin receptor Ser349 Priming not reported TDS349GRGSCDSPSL [72]
Snail (Triggers EMT) Ser96 and Ser100 Ser104 (CKIepsilon) EDS96GKGSQPPSPPS [66,67]
Sp1 Ser728 and Ser732 Thr739 (Erks) proposed LDS728GAGSEGSGTATP [71]
TAZ (transcriptional co-activator with
PDZ-binding motif)
Ser58 and Ser62 Potentially at Ser66 PDS58GSHSRQSSTDS [73,74]
NRF2 Ser338, Ser342. Ser347 SDSGIS338LNTSPSVASP(Mouse) [75,78]
Group 2-Substrates with a S/TXXXS/T motif-GSK3 inhibition would
enhance cell proliferation.
Bcl-3 (b cell lymphoma) Ser394 Ser398 (ERK) SPSSS394PSQSPPRD [32]
Delta catenin-2 Multiple but Thr1078 proposed Priming not reported SSSRT1078PSISPVRV [92,93]
foxp3 Ser270, Ser274. Priming not reported LTKAS270SVASSDKG [89,90]
MafA Ser49, Thr53, Thr57 and Ser61, maybe
also Ser65
Ser65 (possible) LPPGS49LSSTPLSTPCSSVPSSPSFC [86–88]
Mcl-1 Ser159 Thr163 (possible-JNK) STDGS159LPSTPPPAE
GADGSLPSTPPPEEE (mouse)
[82,83]
Myc Thr58 Thr62 (ERK2) ELLPT58PPLSPSRRSG [84,85]
Progesterone receptor A Ser390 Priming not reported EASQS390PQYSFESL [91]
Group 3-Substrates with a S/TXXXS/T motif-GSK3 inhibition would
reduce cell proliferation.
PHLPP1 Ser847 and Thr851 Ser867 and Ser869 (maybe
CK1)
PHVQS847VLLTPQDEFFILGSKGLWDSLSVEEA [99,100]
Smad4 Thr273, Thr269 and Thr265 Thr277 (Erks) HHNST265TTWTGSRTAPYTP [94–96]
Group 4-Substrates with a S/TXXXS/T motif-their GSK3 regulation is
related to cellular stress
HIF1a Ser551, Thr555, and Ser589 Priming not reported KNPFS551TQDSDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSASPESASP [101]
LPCAT1 (Lysophosphatidyl
cholineAcyltransferase1)
Ser178 Ser182 FVSRS178DQDSRRKTV [104]
RASSF1C Ser19 and Ser23 Priming not reported STTSS19GYCSQEDSDSE [103]
REDD1 Ser19, and/or Thr23, and/or Thr25. Priming for Ser19 may occur
at Thr23.
SSPSS19LPRTPTPDRPPRS [102]
Group 5-Substrates with a S/TXXXS/T motif-their GSK3 regulation is
related to development and circadian rhythm
Ci-155 (Dros. melanogaster) Ser852, and Ser884 and 888. Ser856 (PKA)Ser892
(PKA)
SMQS852RRSSQSSQVSS
DPIS884PGCSRRSSQMS
(Dros. melanogaster sequence)
[106,107]
CRY-2 Ser553 Ser557 RPLPS553GPASPKRK [105]
Gli3 (human homologue of ci155) Ser858, Ser870, and Ser890. Ser862, Ser874, and Ser894.
(all PKA)
AYLSS858RRSSGISPCFSS870RRSSEASQ
STDAS890RRSSEASQ
[108]
PAPC Ser816 and Ser820 Priming not reported MGHIS816TKDSGKGD [109]
Group 6-Substrates that are degraded following phosphorylation by GSK3
but lack a consensus S/TXXXS/T motif
Oma1 Thr339 Thr239 proposed SAGST339PSQD (C.elegans sequence)
ARPST239PDE
[111]
(continued on next page)
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The proposed targets of the GSK3-b-TrCP axis can be classified
by the phosphodegron sequence that provides the connection
between substrate, GSK3 and b-TrCP. We will discuss the proteins
in three groups: firstly, those with the proposed ‘perfect’ b-TrCP
binding sequence (DSGXXS); secondly, those with a minimal S/
TXXXS/T sequence (and these are sub-divided by the functional
result of their regulation by GSK3); thirdly, those lacking the dual
phosphorylation motif (Table 1).
4.3.1. Substrates with the DSGXXS motif
As mentioned above, the proposed motif for b-TrCP binding is a
doubly phosphorylated DSGXXS sequence where X is any amino
acid, and as this closely resembles the GSK3 consensus sequence
(SX3or4S-phos) it seems reasonable to propose that this phosphode-
gron is central to allowing degradation by a GSK3 and b-TrCP
dependent mechanism. One could therefore predict that the pres-
ence of the DSGXXS motif within a protein, where phosphorylation
occurs at the C-terminal Ser, would enhance subsequent phospho-
rylation at the N-terminal Ser by GSK3, binding of b-TrCP, poly-
ubiquitination and degradation. Gumbiner and colleagues per-
formed an in silico search for protein sequences containing ‘‘D/ES
GXXS/TXXXS/TXXXS/T”, and identified 38 proteins with this
sequence (and with evolutionary conservation) [18]. This list
includes b-catenin and snail (which were used to generate the
search string) and two other proteins where the stability was
already proposed to be regulated by GSK3 or Wnt. The remainder
have still to be formally confirmed as GSK3-b-TrCP targets but
illustrate the possibility that there are several more GSK3-b-TrCP
target proteins remaining to be characterised. Equally, if one con-
siders that only 7 out of the 29 proteins listed in Table 1 contain
the precise DSGXXS sequence then there may well be dozens more
to be found. It is noteworthy that dysregulation of all 7 of these
DSGXXS containing proteins, plus NRF2 (that has a DSGXXS-like
motif), are strongly associated with aspects of neoplastic disease,
something that is also well established for dysregulated b-TrCP
[62].
b-Catenin is a multifunctional protein involved in transcrip-
tional control but also gap junction structure. Intracellular
b-catenin is normally sequestered by a destruction complex that
includes Axin and APC as well as the protein kinases CK1 and
GSK3. CK1 phosphorylates b-catenin within this complex at
Ser45, which targets it for sequential GSK3 phosphorylation at
Thr41, Ser37 and finally Ser33 [20]. The phosphorylation of Ser37
and Ser33 generates the phosphodegron that binds b-TrCP thereby
promoting poly-ubiquitination and proteasomal degradation
(Fig. 1). This mechanism regulates the transcriptional activity of
b-catenin (not the gap junction structural function) and is
regulated by Wnt signaling. Wnt proteins stabilize intracellular
b-catenin either by destabilising the complex to separate GSK3
from b-catenin or mono-ubiquitinating GSK3-b-TrCP, both of
which have the same outcome of reducing phosphorylation and
ubiquitination of b-catenin [11,63]. The b-catenin is then free to
go to the nucleus and regulate target gene transcription. This
was the first GSK3 substrate found to be regulated in concert with
b-TrCP. Importantly mutations in b-catenin most closely associated
with neoplastic disease lie within the phosphodegron sequence,
primarily Ser33, Ser37, Thr41 and Ser45 mutated to non-
phosphorylatable residues, which would stabilize the b-catenin
[64].
The chromatin helicase DNA-binding factor (CHD1) regulates
epigenetic modifications of chromatin. Ectopic GSK3 expression
resulted in b-TrCP-mediated poly-ubiquitination and degradation
of CHD1, while GSK3 inhibition reduced poly-ubiquitination and
stabilized CHD1. In normal cells PTEN reduces Akt signaling which
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GSK3-mediated phosphorylation of two CHD1 phosphodegrons,
resulting in CHD1 degradation via the b-TrCP-mediated
ubiquitination-proteasome pathway. PTEN deficiency (often found
in neoplastic disease) results in hyperactivity of Akt, reduction in
GSK3 activity, and stabilization of CHD1, which in turn engages
the trimethyl lysine-4 histone H3 modification to activate tran-
scription of the pro-tumorigenic TNF-NF-jB gene network [65].
Thus, CHD1 depletion through inhibition of Akt and re-activation
of GSK3 could reduce growth and survival of PTEN-deficient pros-
tate and breast cancers.
Snail (a zinc-finger transcription factor) triggers the epithelial-
mesenchymal transition (EMT) during embryonic development
through its inhibition of E-cadherin expression [66,67]. The pheno-
typic changes of increased motility and invasiveness of cancer cells
are reminiscent of the EMT suggesting a possible link between
Snail dysfunction and cancer. Snail is one of the EMT factors whose
dysregulation is proposed to contribute to the initiation of specific
cancers [68]. GSK3 b binds to and phosphorylates Snail at two
phosphodegron motifs [66]. Phosphorylation of the first motif
(Ser96-Ser100) regulates its b-TrCP-mediated poly-ubiquitination,
whereas phosphorylation of the second motif controls its subcellu-
lar localization. A variant of Snail which lacks regulation by phos-
phorylation is much more stable and resides exclusively in the
nucleus, thereby inducing EMT. Furthermore, inhibition of GSK3
results in the upregulation of Snail and downregulation of E-
cadherin in vivo [66]. Thus, Snail and GSK3 may be regulated by
many signaling pathways that lead to EMT. Importantly CK1 phos-
phorylation of Snail at Ser104 is required for the subsequent GSK3
phosphorylation at Ser100 and then Ser96, creating the doubly
phosphorylated DSGXXS motif with enhanced binding to b-TrCP
[67]. Specific inhibition or depletion of CK1e inhibits the phospho-
rylation and degradation of Snail and promotes cell migration,
demonstrating that targeting the priming phosphorylation of a
GSK3 substrate can alter its regulation by GSK3 without changing
the activity of the GSK3-b-TrCP proteins themselves.
FGD1 gene disruption results in Faciogenital Dysplasia (FGDY;
Aarskog syndrome), a skeletal dysplasia and multiple congenital
anomaly syndrome, implying a crucial role in aspects of mam-
malian development. The gene product contains domains that indi-
cate it is a guanine nucleotide exchange factor (GEF) for the Rho
family GTPase Cdc42. FGD1 contains a DSGXXS motif and is recog-
nized by b-TrCP when the two serine residues in this sequence are
phosphorylated. This promotes ubiquitination and subsequent
degradation of GEF by the proteasome [69]. The ubiquitination
and degradation of GEF is regulated by GSK3 inhibitors. Subse-
quent work found that FGD3, a homologue of FGD1, is degraded
following polyubiquitination by b-TrCP, and this is also regulated
by Lithium Chloride (LiCl), a non-selective GSK3 inhibitor [70].
FGD3 has highly homologous domains to FGD1 that suggest it is
also likely to be a GEF for Cdc42, as well as having the DSGXXS
motif. However, when overexpressed, FGD3 induces distinct cellu-
lar phenotypes to FGD1 in HeLa cells, indicating they possess
somewhat distinct cellular roles. Despite this, it appears their
destruction may be coordinated through the GSK3-b-TrCP axis.
Sp1 is a ubiquitous transcription factor linked to the regulation
of dozens of genes. Glucose starvation or treatment with the thia-
zolidinedione derivative (OSU-CG12) both induce specific binding
of Sp1 to b-TrCP followed by Sp1 degradation in LNCaP cells [71].
In addition, ectopic expression of b-TrCP enhances the ability of
OSU-CG12 to facilitate Sp1 degradation, while suppression of
endogenous b-TrCP function, using either a dominant-negative
mutant or small interfering RNA-mediated knockdown, blocks
OSU-CG12-facilitated Sp1 ubiquitination and/or degradation. Sp1
contains a C-terminal conventional DSG destruction box ((7 2 7)D
SGAGS(7 3 2)) that mediates b-TrCP recognition and this isphosphorylated by GSK3 in vitro [71]. Phosphorylation of Thr739
by ERKs appears critical for Sp1 degradation and it may be that this
acts as a ‘distant’ priming site for GSK3 phosphorylation of Ser732
and Ser728. Alternatively, there may be a third kinase which is
actually responsible for Ser732 phosphorylation in vivo, providing
priming for GSK3 phosphorylation of Ser728. If so, this would
mean there is a requirement for three different kinases to phos-
phorylate Sp1 before it was shuttled to the proteasome.
The prolactin receptor (PRLr) is a cytokine receptor best known
for its role in mediating prolactin control of mammary growth.
However, it is expressed in many cell types besides mammary
cells, including pancreatic beta cells and adipose tissue, and so it
contributes to reproduction, islet differentiation, fat storage and
immunomodulation. GSK3 phosphorylates PRLr on Ser349
in vitro, and this phosphorylation is required for the recognition
of PRLr by b-TrCP, as well as for PRLr ubiquitination and degrada-
tion [72]. PRLr is relatively abundant in human breast cancer,
potentially due to decreased phosphorylation of Ser349. Constitu-
tive oncogenic signaling downstream of ErbB2 and Ras stabilizes
PRLr via inhibitory phosphorylation of GSK3 b on Ser9. Meanwhile
progressive inactivation of GSK3 b correlates with elevated levels
of PRLr protein in human breast cancer tissue [72]. Interestingly,
although the sequence around Ser349 (DS349GRGS) is a perfect
DSGXXS motif there is no report as yet of phosphorylation of
Ser353 being required for GSK3 to phosphorylate PRLr or for bind-
ing to b-TrCP. One might predict the existence of a priming kinase
that initiates the pathway by phosphorylation of Ser353.
TAZ (transcriptional co-activator with PDZ-binding motif; also
known as WWTR1) is a transcriptional co-activator mainly con-
trolled by the Hippo pathway. The Hippo pathway is a key regula-
tor of organ homeostasis through modulation of cell proliferation
and apoptosis. TAZ is inhibited by large tumour suppressor
(LATS)-dependent phosphorylation, leading to cytoplasmic reten-
tion and ubiquitin-dependent degradation. The LATS kinase, a core
component of the Hippo pathway, phosphorylates a C-terminal
sequence in TAZ to promote its degradation. However, there is also
an N-terminal DSGXXS sequence within TAZ that is regulated by
PI3K signaling [73]. GSK3 phosphorylates this sequence in TAZ,
promoting binding to b-TrCP, ubiquitination and degradation.
PI3K signaling inhibits GSK3 thereby reducing phosphorylation of
TAZ and stabilizing the transcriptional coactivator. TAZ can also
be regulated by Wnts [74], again suggesting that the GSK3-b-
TrCP axis controls TAZ stability.
One protein with a DSGXXS-like motif is Nuclear factor-
erythroid 2 p45-related factor 2 (NRF2, encoded by the gene
NFE2L2), a cap‘n’collar (CNC) basic-region leucine zipper (bZIP)
transcription factor that mediates intracellular redox homeostasis.
It is best known for its activation during oxidative stress, but it is
becoming more appreciated for its contribution to other cellular
stress responses [75]. NRF2 is activated by oxidative stressors
and electrophilic agents, and mediates adaptation to stress by pos-
itively regulating cellular antioxidant defences and metabolism
through its control of over 250 target genes in response to various
stressors. These gene products regulate a host of cytoprotective
functions including; drug detoxification, GSH-based antioxidants,
Thioredoxin-based antioxidants, pentose phosphate shunt, NADPH
generation, purine synthesis, iron sequestration, proteasome sub-
unit production, apoptosis, serine/glycine biosynthesis and
autophagy.
In most cell culture conditions NRF2 has a very short half-life
primarily due to rapid ubiquitination and 26S mediated proteaso-
mal degradation. However, upon exposure to oxidative stress con-
ditions, or to thiol-reactive compounds, nuclear levels of NRF2
protein increase thereby driving antioxidant response element
(ARE)-driven gene expression. Under non-stressed conditions the
ubiquitination of NRF2 is predominantly performed by cullin-3
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substrate adaptor protein for the CUL3 RING-box 1 (RBX1) E3
ligase complex. KEAP1 functions as a stress sensor, under oxidative
stress conditions several key cysteine residues on the surface of
KEAP1 are modified. The modified KEAP1 loses its ability to induce
cullin-3 ubiquitination of NRF2. As a consequence, the half-life of
newly synthesised NRF2 protein is extended and the expression
of ARE-driven NRF2-target genes is induced.
Besides KEAP1, NRF2 is also targeted for proteasomal degrada-
tion through ubiquitination by cullin-1, using b-TrCP as a substrate
adaptor. However, in this instance, ubiquitination of NRF2 by
cullin-1 requires the transcription factor to be first phosphorylated
by GSK3 in order to generate the phosphodegron to which b-TrCP
binds (Fig. 1). In NRF2 peptide pull down experiments, we found
that NRF2 possesses two b-TrCP binding sequences within its
Neh6 domain [76]. Peptides containing DSAPGS378 or DSGIS338
(n.b. amino acid numbering based on mouse Nrf2) were able to
interact with b-TrCP, with the latter exhibiting much higher affin-
ity if it were doubly phosphorylated [76]. GSK3 could phosphory-
late Ser338 (and Ser342) of the Neh6 domain implying that this
provides at least part of the modification that enhances b-TrCP
binding [76,77]. Recent work has also demonstrated the require-
ment for priming of NRF2 at Ser347 in order to initiate the phos-
phorylation by GSK3 (Fig. 1 and HR and Sudhir Chowdhry
unpublished data). NRF2 priming is likely to be mediated by mem-
bers of the CMGC family of kinases and provides an additional
regulatory point for control of NRF2 stability [76,78]. Inhibition
of either GSK3 or the priming kinase would stabilize NRF2.
There are two key differences between NRF2 and the GSK3-b-
TrCP targets listed above: firstly, it is a DS335GXS338 motif;
secondly, robust evidence that GSK3 directly phosphorylates the
N-terminal Ser (Ser335) within the b-TrCP binding motif is still
lacking. Indeed, the spacing between the Ser residues in the
DS335GXS338 is less than three amino acids, indicating it is highly
unlikely that GSK3 phosphorylates Ser335 using Ser338 as the
‘priming site’. However, there is strong evidence that GSK3 phos-
phorylates Ser338 using Ser342 as a priming site [76], and this is
crucial to allow b-TrCP-mediated NRF2 degradation. The identity
of the kinase that phosphorylates Ser335 remains uncertain.
Interestingly, the related CNC-bZIP transcription factor NRF1 is
also degraded by the proteasome in a b-TrCP-dependent manner
through a DSGLS motif [79], but in this case the recognition motif
is phosphorylated by casein kinase 2, and not GSK3 [80].
4.3.2. Substrates with a minimal S/TXXXS/T motif
The b-TrCP binding motif is clearly more degenerate than the
‘classic’ DSGXXS motif. For example, our work on NRF2 found
DSGXS to be a high affinity interaction sequence after dual phos-
phorylation [76], and additional non-consensus b-TrCP binding
sequences, that do not involve phosphorylation have been
reported, including in NRF2 [76]. However, recent structural
studies have confirmed that dual phosphorylation greatly
enhances b-TrCP binding affinity, while it also established that dif-
ferent residues on b-TrCP are involved in binding different phos-
phorylated substrates [60]. This is consistent with the precise
DSGXXS sequence not being prescriptive for b-TrCP targeting,
and explains the large number of phosphoproteins in Table 1 that
are degraded in a b-TrCP-dependent fashion despite the fact they
lack this exact consensus motif. Sixteen of the proteins in Table 1
that have a SXXXS motif (in addition to the 7 with DSGXXS plus
NRF2 with DSGXS) exhibit enhanced degradation (in a b-TrCP-
dependent manner) when double phosphorylation of this motif is
present. Moreover, a further two (Progesterone receptor A and
d-catenin) have the potential to be doubly phosphorylated but as
yet are only reported to be phosphorylated on the N-terminal resi-
due within the SXXXS sequence (by GSK3). Thus, amongst the 27proteins in Table 1 where the GSK3 target sequence is known, a
total of 25 are likely to share the dual phosphorylation as central
to their destruction by the proteasome.
However there doesn’t appear to be any consistent pattern in
the primary sequence of the ‘phosphodegron’ (outside the dual
phosphorylation sites) to explain recognition of this series of pro-
teins by b-TrCP (Table 1). These proteins only account for around
a quarter of the 100 or so proposed GSK3 substrates (almost all
of which contain this minimal S/TXXXS/T motif), and the rest do
not appear to be poly-ubiquitinated and degraded upon phospho-
rylation [3]. This means that there must be a structural component,
in addition to dual phosphorylation, that dictates whether b-TrCP
ubiquitinates the phosphorylated GSK3 substrate.
The simplest explanation is the existence of a scaffold protein(s)
that enhances interactions between GSK3, b-TrCP and the sub-
strates for degradation, in an analogous fashion to the canonical
Wnt signaling complex [11]. Indeed, the axin scaffold may bring
many additional GSK3-b-TrCP targets in close proximity to GSK3
and b-TrCP, and allow their regulation by Wnts [18,81]. However,
there are few reports of b-TrCP or GSK3 containing complexes
which could co-ordinateWnt-independent regulation of GSK3 sub-
strates, although one would predict these may be difficult to iso-
late as they would be short-lived and their formation
dynamically regulated. It is possible that the physiological func-
tions of these substrates may provide clues as to how, and why,
they may be co-ordinately regulated. Many of the substrates in
Table 1 are involved in cell growth, differentiation and/or cell
death, and it may be that they are regulated by a common mecha-
nism related to the control/timing of these processes in order to co-
ordinate their destruction.
4.3.2.1. Proteins with an S/TXXXS/T motif whose stability would be
increased by GSK3 inhibition with subsequent enhancement of cell
proliferation. Mcl-1 is an anti-apoptotic member of the Bcl2 family,
that is lost from cells exposed to UV irradiation [82]. Phosphoryla-
tion at Thr163 by JNK primes Mcl-1 for phosphorylation at Ser159
by GSK3, generating a phosphodegron recognized by b-TrCP, lead-
ing to ubiquitination and degradation of Mcl-1 in response to UV
stress. This links the pro-apoptotic activity of JNK, and the pro-
survival activity of the Akt pathway that inhibits GSK3 [82]. In
addition, phosphorylation of Mcl-1 by GSK3 in response to Akt
inhibition also leads to b-TrCP mediated degradation of Mcl-1.
Importantly the induction of apoptosis by Akt inhibitor in NSLCS
cells required GSK3 activity, providing evidence for GSK3 regula-
tion of Mcl-1 dependent apoptosis [83].
BCL-3 is a proto-oncogene that regulates immune cell growth
through its interaction with NF-kB [32]. Certain B cell leukemias
are associated with DNA translocation of the bcl-3 gene. Interest-
ingly phosphorylation of BCL-3 modulates its association with
HDAC1, -3, and -6 and attenuates its oncogenicity by selectively
controlling the expression of a subset of target genes such as SLPI
and Cxcl1 [32]. GSK3-mediated BCL-3 phosphorylation occurs fol-
lowing priming by ERKs and promotes polyubiquitination and
degradation. Although degradation requires the generation of the
doubly phosphorylated phosphodegron favoured by b-TrCP, confir-
mation of b-TrCP as the E3 ligase responsible remains to be
confirmed.
Myc is a transcription factor that enhances expression of a
broad spectrum of genes involved in the biogenesis of nucleotides
and ribosomes, thereby stimulating protein translation. In addi-
tion, Myc induces the expression of several cyclins and suppresses
the transcription of cyclin-dependent kinase inhibitors, thereby
promoting exit from quiescence and stimulating progression
through G1 phase. GSK3 phosphorylates Thr58 of Myc and this is
enhanced by priming at Thr62, probably by ERKs. Initially phos-
phorylation of Thr58 of Myc by GSK3 was reported to enhance
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degradation of Myc, primarily during the G1 phase of the cell cycle
[84]. More recently b-TrCP was also shown to bind to and enhance
ubiquitination of c-Myc but modifying alternative residues of Myc
to SCFfbw7 [85]. This had the effect of promoting Myc stability, thus
alternative ubiquitination events at the N-terminus of Myc in
response to phosphorylation promote opposite effects on its stabil-
ity. It appears that the GSK3 regulation of c-Myc may be to target it
for labelling by more than one Fbox protein, which ubiquitinate on
different residues of c-Myc and have contrasting outcomes on pro-
tein stability [85].
The Maf oncoproteins (i.e. large Maf proteins, as opposed to
small Maf proteins that heterodimerize with CNC-bZIP transcrip-
tion factors) are transcriptional regulators of the AP-1 superfamily.
They regulate developmental, metabolic, and tumorigenic path-
ways in multiple tissues and are overexpressed in about 50% of
human multiple myelomas [86]. MafA controls insulin production
in the pancreatic beta cells in response to glucose. Paradoxically,
phosphorylation by GSK3 at multiple sites induces MafA oncogenic
potential but at the same time leads to MafA ubiquitination and
degradation [86–88]. Low glucose enhances MafA phosphorylation
and degradation in Min6 cells, reducing insulin gene transcription.
Meanwhile GSK3 inhibitors reduce the phosphorylation and degra-
dation of c-Maf in multiple myeloma cells but also reduce the
inherent oncogenicity of c-Maf, as they reduce proliferation of
the cells [88]. While phosphorylation by GSK3 results in 4 or 5
phosphorylated residues lying in series with 4 amino acid spacing
(S49-T53-T57-S61-S65) it has not yet been confirmed that b-TrCP
is the E3 ligase responsible for targeting to the proteasome. GSK-
3-mediated Maf phosphorylation also modulates extracellular
matrix remodeling which could modify cancer progression [86].
Foxp3-expressing Treg cells limit anti-tumour responses and
allow the persistence and growth of cancer. Phosphorylation of
Foxp3 by GSK3 promotes b-TrCP binding and polyubiquitination
leading to degradation by the proteasome. EGF-like growth factor
Amphiregulin (AREG), which is frequently upregulated in human
cancers, reduces GSK3 activity and stabilizes Foxp3 [89]. Therefore
interfering with the regulation of Foxp3 by AREG in cancer patients
could lead to Foxp3 protein degradation in Treg cells and provide a
potential novel therapeutic target for cancer treatment [89,90].
Progesterone receptors (PR-A) are over expressed in Brca1-
deficient mammary epithelial cells. BRCA1 germ line mutations
increase the risk of breast and ovarian cancer, whereas treating
with anti-progesterone delays mammary tumorigenesis in Brca1/
p53 knock-out mice. All of these data indicate that progesterone
has a critical role in initiation and/or progression of breast carcino-
genesis. GSK3-mediated phosphorylation of Ser390 in PR-A pro-
motes its ubiquitination and degradation [91]. Although no
priming event was reported for Ser390 phosphorylation, a Ser resi-
due at position 394 exists that would lend itself to a priming mech-
anism. Meanwhile, expression of a PR-AS390A phosphorylation
deficient mutant in human breast MCF-10A epithelial cells
enhances proliferation and formation of aberrant acini structures
in 3D culture. Reduced phosphorylation of Ser390 of PR-A and rel-
atively low GSK3 b activity is found in the Brca1-deficient mam-
mary gland [91]. This is consistent with Brca1 enhancing GSK3
phosphorylation of PR-A and promoting its subsequent degrada-
tion. Brca1 deficiency would associate with enhanced PR-A expres-
sion and higher sensitivity to progesterone.
d-Catenin polyubiquitination occurs following phosphorylation
at Thr1078 by GSK3 and generation of the phosphodegron which
recruits b-TrCP1 [92]. The interaction between d-catenin and
b-TrCP is enhanced by phosphorylation at Thr1078 [93]. No prim-
ing has been reported but there is a phosphorylatable residue that
is located four residues C-terminal to the proposed GSK3 target
site. d-Catenin can be degraded by the proteasome and also bylysosomes. Numerous downstream processes are regulated by
d-catenin, including control of cognitive function, E-cadherin sig-
naling and angiogenesis. Enhanced d-catenin stability is associated
with several neoplastic diseases including those of prostate, lung,
ovary, brain and colon.
4.3.2.2. Proteins with an S/TXXXS/T motif whose stability would be
increased by GSK3 inhibition with subsequent reduction in cell
proliferation. Smad4/DPC4 is an essential transcription factor in
the TGF-b pathway and is frequently mutated or deleted in pros-
tate, colorectal, and pancreatic carcinomas. Smad4 activity is
directly regulated by the Wnt and fibroblast growth factor (FGF)
pathways through hierarchical phosphorylation by GSK3 and Erk.
FGF activates ERK, which primes three sequential GSK3 phospho-
rylations on Smad4 that generate a Wnt-regulated phosphodegron
bound by b-TrCP [94]. In Xenopus embryos, these Smad4 phospho-
rylations regulate germ-layer specification and Spemann organizer
formation. Human Smad4 mutations that enhance phosphoryla-
tion at Thr273/Thr269 and Thr265 are less stable, inactivate TGF-
b signaling and are associated with tumourigenesis [95]. This can
be corrected with GSK3 inhibition providing a novel therapeutic
opportunity in Smad4 related cancer [96]. Interestingly the related
proteins Smad1 and Smad3 are also phosphorylated by GSK3 in
similar sequences to the Smad4 motif, thereby targeting them for
destruction, although the priming for these could be ERKs or
Cdk8/9, while ubiquitination appears to be performed by the Smad
specific HECT E3 ligases of the Smurf family [97,98].
PHLPP1 is a member of a family of Ser/Thr protein phosphatases
(PPases) that serve as tumour suppressors by negatively regulating
Akt signaling and its expression is reduced in colorectal cancer [99].
b-TrCP recognizes PHLPP1 only after phosphorylation of PHLPP1 by
CK1 and GSK3, resulting in enhanced degradation via the protea-
some [100]. Ectopic expression of a degradation-deficient PHLPP1
mutant in colon cancer cells enhances dephosphorylation of Akt
and inhibits cell growth. Therefore, the GSK3-b-TrCP destruction
of PHLPP1 enhances Akt activity which would paradoxically pro-
mote greater GSK3 inhibition. This suggests the existence of a neg-
ative feedback loop involving Akt and GSK3; when Akt is activated
it would inhibit GSK3 and stabilize the Akt PPase, thereby turning
off the Akt signal and reducing growth.
4.3.2.3. Proteins with the S/TXXXS/T motif whose GSK3-mediated
destruction is related to cellular stress. Hif1a is a critical factor that
initiates an adaptive and protective transcriptional programme to
protect cells against changes in O2 tension (in particular hypoxia).
Under normal O2 tension it is rapidly degraded following polyubiq-
uitination by the E3 ligase, VHL. However, phosphorylation of
Hif1a by GSK3 induces ubiquitination and proteasomal degrada-
tion, independent of VHL, and this pathway is proposed to underlie
regulation of Hif1a action by growth factors, nitric oxide and hor-
mones [101].
REDD1 (regulated in development and DNA damage responses
1) is a hypoxia-inducible factor-1 target gene, with a protein
half-life of <15 min. It has a crucial role in inhibiting mammalian
target of rapamycin complex 1 (mTORC1) signaling during hypoxic
stress through regulation of TSC proteins. Other environmental
stresses such as energy stress, glucocorticoid treatment and reac-
tive oxygen species can enhance REDD1 gene transcription. REDD1
is subject to ubiquitin-mediated degradation mediated by b-TrCP,
dependent on phosphorylation by GSK3 [102]. REDD1 degradation
is crucially required for the restoration of mTOR signaling as cells
recover from stress.
RASSF1A [Ras association (RalGDS/AF-6) domain family mem-
ber 1A] and RASSF1C are two ubiquitously expressed isoforms of
the RASSF1 gene. RASSF1A is implicated in the regulation of apop-
tosis, microtubule stability and cell cycle arrest. RASSF1C is a very
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proteasome. RASSF1C degradation is enhanced when cells are
exposed to stress signals, such as UV irradiation [103]. Mule, a
HECT (homologous with E6-associated protein C-terminus) family
E3 ligase ubiquitinates RASSF1C under normal conditions. In con-
trast both Mule and b-TrCP target RASSF1C degradation in
response to UV irradiation and this requires GSK3 phosphorylation
of RASSF1C at Ser19 and Ser23 [103]. Therefore, Mule and b-TrCP
target RASSF1C for degradation in response to UV irradiation/
DNA damage following phosphorylation by GSK3. Priming was
not reported for RASSF1C however GSK3 is not regarded as an
UV regulated kinase so it remains possible that an unidentified
UV dependent priming mechanism exists for recognition by GSK3.
Lysophosphatidylcholine Acyltransferase 1 (LPCAT1) is a lipid
synthesizing enzyme key in the production of the bioactive surfac-
tant phospholipid, dipalmitoylphosphatidylcholine (DPPtdCho)
and hence plays a vital role in lung physiology. It is a member of
the 1-acyl-sn-glycerol-3-phosphate acyltransferase family con-
verting lysophosphatidylcholine to phosphatidylcholine in the
presence of acyl-CoA. This process is also important in the synthe-
sis of platelet-activating factor (PAF). Lipopolysaccharide (LPS)
treatment of cells causes LPCAT1 degradation, altering the surfac-
tant properties of the lung. Phosphorylation at Ser178 by GSK3 fol-
lowing priming at Ser182 generates the b-TrCP binding site and
enhances polyubiquitination and degradation of the protein in
response to LPS [104]. Furthermore, elevated expression of LPCAT1
may contribute to the progression of oral squamous cell, prostate,
breast, and other human cancers.
4.3.2.4. Proteins which are destroyed by GSK3 mediated-phosphory-
lation with vital functions in development and circadian
rhythm. Cryptochrome 1 (CRY1) and 2 (CRY2) are flavoproteins
that act as essential components of the central and peripheral cir-
cadian clocks for generation of circadian rhythms in mammals
[105]. They are transcriptional repressors of the transcriptional
activators CLOCK and BMAL1 and together these proteins generate
a negative feedback loop whose timing provides circadian rhythm
to mammalian cells. Mouse cryptochrome 2 (mCRY2) protein accu-
mulates overnight and is phosphorylated at Ser557 in liver. Phos-
phorylation at Ser557 peaks around 4 h prior to peak protein
accumulation and allows subsequent phosphorylation at Ser553
by GSK3, resulting in degradation of mCRY2 by the proteasome.
The priming kinase involved is not yet identified although Erk
can phosphorylate Ser557 in vitro [105]. Inhibitory phosphoryla-
tion of GSK3 at Ser-9 exhibits a circadian rhythmwith a peak when
Ser-557 of mCRY2 is highly phosphorylated. The dual phosphoryla-
tion of mCry2 is associated with polyubiquitination (although the
E3 ligase responsible is yet to be confirmed) and degradation by
the proteasome [105]. The control of the half-life of CRY2 protein
contributes to the timing of the circadian rhythm.
In Drosophila, Cubitus interruptus (Ci) is a key transcriptional
regulator of limb development. The long form (Ci-155) is an activa-
tor of gene transcription while a shorter proteolytic fragment is a
repressor [106]. Modulation of the relative proportions of each
form of Ci co-ordinates different stages of limb development.
PKA phosphorylation of Ci-155 on at least two sites primes it for
subsequent phosphorylation by GSK3 and ubiquitination by the
Drosophila homologue of b-TrCP called slimb [106,107]. This
enhances the proteolytic processing, generating the smaller repres-
sor form of Ci. Hedgehog (Hh) signaling opposes this proteolysis by
promoting dephosphorylation of the PKA and GSK3 target sites.
Gli3 is the human homologue of Ci-155, and is the only Gli iso-
form that can be processed to a repressor. It also regulates limb
development under the control of Shh signaling. In a similar fash-
ion to the Drosophila Hh Ci-155 system, PKA phosphorylation of
Gli3 on several sites primes it for subsequent phosphorylation byGSK3 and CK1 [108]. This promotes b-TrCP binding and proteolytic
processing, generating the smaller repressor form.
Paraxial protocadherin (PAPC) is involved in gastrulation cell
movements during early embryogenesis. It is first expressed in
the dorsal marginal zone at the early gastrula stage and subse-
quently restricted to the paraxial mesoderm in Xenopus and zebra-
fish. PAPC is also regulated at the protein level and is degraded and
excluded from the plasmamembrane in the axial mesoderm by the
late gastrula stage. PAPC cellular location, ubiquitination and sta-
bility were all affected by treatment with a GSK3 inhibitor (BIO)
or expression of a dnGSK3. These deficits were reversed by intro-
duction of a Ser816Asp/Ser820Asp ‘double phosphorylation mimic’
mutant PAPC [109]. The poly-ubiquitination of PAPC required b-
TrCP, but the possible priming of PAPC to allow GSK3 to recognize
it as a substrate has not been investigated. The control of PAPC by
phosphorylation/ubiquitination is essential for normal Xenopus
gastrulation cell movements [109].4.3.3. GSK3 substrates that are destroyed following phosphorylation
but lack a consensus S/TXXXS/T motif, or evidence for b-TrCP binding
There are two proteins in Table 1 that lack the primary
sequence around the GSK3 target site to create a dual phosphory-
lated b-TrCP binding motif yet they are reported to be degraded in
response to phosphorylation by GSK3. Specifically, Oma-1 and
p21Cip1 contain a Glu or Asp three or four residues C-terminal to
the phosphorylated serine and thus it is conceivable that the acidic
amino acid side chain can partially mimic a phosphorylated serine
and enhance phosphorylation by GSK3. This remains to be con-
firmed and in our experience an acidic residue does not prime pep-
tide substrates to enhance phosphorylation by GSK3 (Sutherland
unpublished data). In addition, the evidence that the degradation
reported is mediated by b-TrCP, or even by ubiquitination is still
lacking.
Regulation of the DNA repair protein p21Cip1 by the phospho-
inositide 3-kinase (PI3K)/AKT pathway is crucial for the proper
control of endothelial cell (EC) proliferation and survival [110].
p21Cip1 is a short-lived CDK binding protein with a high proteaso-
mal degradation rate. The PI3K inhibitors LY294002 and wortman-
nin reduced p21Cip1 protein abundance in human umbilical vein
EC. GSK3 phosphorylated p21Cip1 at Thr57 within the CDK binding
domain [110]. Overexpression of GSK3b decreased p21Cip1 protein
levels in EC, whereas LiCl interfered with p21Cip1 degradation and
increased p21Cip1 protein about 10-fold in EC and cardiac myo-
cytes. This suggests that GSK3 triggers p21Cip1 degradation, while
stimulation of Akt increases p21Cip1 protein levels via inhibitory
phosphorylation of GSK3.
Oma1 has mostly been studied in C. elegans. Oocyte maturation
and fertilization initiates a dynamic and tightly regulated process
in which a non-dividing oocyte is transformed into a rapidly divid-
ing embryo. The zinc finger protein, OMA-1 is expressed only in
oocytes and 1-cell embryos, and is degraded rapidly after the first
mitotic division allowing embryogenesis to proceed normally. The
OMA-1 protein is directly phosphorylated at Thr239 by the DYRK
kinase MBK-2, and this is required both for OMA-1 function in
the 1-cell embryo and its degradation after the first mitosis
[111]. Phosphorylation at Thr239 facilitates subsequent phospho-
rylation of OMA-1 by GSK3, at Thr339 in vitro. Phosphorylation
at both Thr239 and Thr339 are essential for correctly-timed
OMA-1 degradation in vivo. Therefore, GSK3 regulation of Oma1
is required for correctly-timed OMA-1 degradation in one cell
embryos [111]. However, it is not clear if this occurs in mammalian
cells and it represents a very unusual GSK3 substrate, with non-
consensus ‘priming’ occurring at a very distant residue, as well as
a non-consensus b-TrCP target, lacking the SXXXS motif. Indeed,
the evidence that this is a b-TrCP target is also not yet provided.
Table 2
Inhibitors of GSK3 and potential priming kinase mentioned in the text or that have undergone testing in clinical trials.
Kinase Inhibitor CAS number Potential
specificity
problems
Reported Clinical trials
GSK3 (glycogen synthase kinase 3) CT99021 CAS 252917-06-9 CDK2-CYCLIN A None
Valproic acid/Depakene/
Valproate Semisodium/
Divalproex
CAS 99-66-1/CAS
76584-70-8
NCT00385710 (completion 2010): Phase 2, Treatment of progressive supranuclear palsy
NCT01548066 (completion 2012): Phase 2, for the prevention of hair loss
NCT00088387(completion 2005): Phase 2, in combination with lithium for Alzheimer’s disease
LiCl (Lithium Chloride) CAS 7447-41-8 MNK1
MNK2
SmMLCK
PHK
CHK1
CHK2
EF2K
NEK6
HIPK3
IKK E
TBK1
CK2
PRAK
MAPKAP-K2
NCT02601859 (completion 2016): Phase 3, for the prevention of Alzheimer’s disease onset
NCT01055392 (completion 2009): Phase 2, treatment of Alzheimer’s disease
NCT00088387 (completion 2005): Phase 2, to be used alone or in combination with Divalproex for the
treatment of Alzheimer’s disease
NCT03290963 (estimated end date 2018): Phase 2, to assess the antidepressant effect of lithium in
adults receiving Ketamine
NCT01096082 (completion 2013): Phase 2/3, –treatment of Spinocerebellar ataxia type 3
NCT00870311 (completion 2004): Phase 4, for the treatment of Bipolar disorder
NCT01543724 (completion 2013): Phase 4, for the treatment of Bipolar disorder
NCT01096082 (completion 2013): Phase 2/ 3, for the treatment of Spinocerebellar Ataxia Type 3
Tideglusib/NP031112 CAS 865854-05-3 NCT01049399 (completed 2011): Phase 2, for the treatment of progressive supranuclear palsy (PSP)
NCT00948259 (completed 2009): Phase 1 /2, for the treatment of Alzheimer’s disease
AZD1080 (5) CAS 612487-72-6 AMPK
LCK
MSK1
Phase 1 for Alzheimer’s Disease 2006 (discontinued)
LY2090314 CAS 603288-22-8 NCT01632306 (study terminated): Phase 1/2, in combination with pemetrexad and Carboplatin for the
treatment of Metastatic pancreatic cancer
NCT01214603 (completion 2012): Phase 2, for the treatment of acute leukaemia
CK2 CX-4945 CAS 10009820-21-6 NCT00891280 (completion 2011) Phase 1: advanced solid tumour cancers, Castlemans disease of
multiple myeloma
NCT02128282(completion 2018) : phase 1/2, in combination with cisplatin and gemcitabine in patients
with Cholangiocarcinoma
CIGB-300 CAS 1072877-99-6 NCT01639625 (completion 2016) squamous cell carcinoma or adenocarcinoma of the cervical stage IIA
and IIB with cisplatin phase 2
NCT01639638 (study terminated 2014) phase 2 / 3, for patients with recurrent and non recurrent
genital condyloma
DYRK Epigallocatechin-3-gallate
(EGCG)
CAS 989-51-5 NCT01394796 (completion 2011): Phase 2, for the treatment of Down Syndrome
NCT01699711 (completion 2015): Phase 2, for the treatment of Down syndrome
GSK626616 CAS 1025821–33-3 YAK3 NCT00443170 (completion 2012): Phase 1 for Healthy subjects with Anaemia
CDK5 (cyclin dependent kinase 5) R-roscovitine (Seliciclib) CAS 186692-46-6 CDK2
CK1
DYRK1A
CDK1
NCT00999401 (completion 2018) Phase 1 for advanced solid tumours
NCT00372073 (completion 2012) Phase2: non-small cell lung cancer (NSCLC)
p42/p44 MAPK ERK1/2 GSK1120212 (Trametinib) CAS 871700-17-3 MEK1 NCT03232892 (completion 2021) Phase2: non-squamous Non-small cell lung carcinoma
NCT01958112 (terminated) Phase 2: cervical cancer
NCT01553851 (completion 2015) Phase 2: oral cavity squamous cell cancer
p38-MAPKa/b SCIO-469 (Talmapimod) CAS 309913-83-5 TNF-a
IL-1
COX-2
NCT00043732(completion 2003) Phase 2: evaluation of safety and tolerability in Rheumatoid Arthritis
patients receiving Methotrexate
NCT00095680 (completion 2006) and NCT00087867(completion 2005) Phase 2: as a monotherapy or in
combination with Bortezomib in relapse refractory patients with multiple myeloma
NCT00113893 (completion 2007) Phase 2: treatment for myelodysplastic syndromes
NCT00508768 (completion 2002) Phase 1: for the treatment of Rheumatoid arthritis
NCT00089921(completion 2004) Phase 2: for the treatment of Rheumatoid arthritis
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determined
There are two proteins in Table 1 with an association between
GSK3 phosphorylation, b-TrCP ubiquitination and their degrada-
tion, yet the phosphorylation site and b-TrCP binding site remain
to be verified, namely VEGFR-2 and securin/PTG.
Vascular endothelial growth factor receptor-2 (VEGFR-2) is a
key determinant of the angiogenic response and is decreased in
diabetic hyperglycemic mice exposed to oxidative stress. A phos-
phorylated form of VEGFR-2 was reduced in the mice by hyper-
glycemia and VEGFR-2 protein was reduced in cells directly
exposed to oxidative stress. This coincided with co-location of b-
TrCP and VEGFR-2, and increases in ubiquitination of VEGFR-2
[112]. This reduction of VEGFR-2 protein in response to ROS was
ameliorated by b-TrCP siRNA or treatment with the proteasome
inhibitor MG132 or GSK3 activity inhibitors (LiCl and SB216763).
These data together support the hypothesis that oxidative stress
induces the GSK3-b-TrCP axis to target VEGFR-2 for degradation
[112]. b-TrCP also regulates VEGFR-2 degradation in thyroid cancer
cells [113].
Securin is a chaperone protein which binds to separase to inhi-
bit premature sister chromatid separation until the onset of ana-
phase, and which also modulates cell-cycle arrest after UV
irradiation. At metaphase-to-anaphase transition, securin is tar-
geted for proteasomal destruction by the anaphase-promoting
complex or cyclosome (APC/C), allowing activation of separase.
UV radiation induces a marked reduction of securin protein, while
GSK3 inhibitors prevent this securin degradation [114]. b-TrCP
ubiquitinates securin in vivo and is the ligase responsible for
securin degradation after UV irradiation. While GSK3 may mediate
this degradation of securin, the site(s) phosphorylated by GSK3 is
not known [114]. Securin has a proposed unconventional b-TrCP
recognition motif (DDAYPE). If this is truly the motif that mediates
b-TrCP binding, then it is unclear what role GSK3 phosphorylation
would play in the control of securin.5. Potential input from priming
The prior phosphorylation of a substrate at a residue 4 or 5
amino acids C-terminal to the GSK3 target site greatly enhances
the rate of phosphorylation by GSK3. This priming occurs on the
majority of validated substrates of GSK3 and introduces an oppor-
tunity for substrate selective control of GSK3 action, especially
where priming is an essential condition for the substrate to be rec-
ognized by GSK3 [3]. There are many different priming kinases
identified for GSK3 substrates (see Section 2.2), thus increases in
GSK3 activity would not necessarily result in similar increases in
phosphorylation of each of the primed GSK3 targets (if priming
was limiting). Indeed, it follows that distinct groups of GSK3 sub-
strates will exist in cells (defined by the regulation of priming)
which will respond to increases in GSK3 activity in different ways.
However, this is a neglected aspect of GSK3 function, which is
rather surprising given the enormous interest over the past 20
years in GSK3 as a potential target in the clinic. This lack of study
may be related to the fact that priming of the original GSK3 sub-
strate, glycogen synthase, is considered constitutive, and thus
priming has always been seen as a relatively inert aspect of GSK3
action.
However, of the 27 proteins regulated by the GSK3-b-TrCP axis
where the GSK3 site is known there are 25 substrates where prim-
ing could exist (Table 1). Yet a priming kinase was only discussed
for 10 of these substrates, and in this small group there are 6 dif-
ferent priming kinases proposed. b-Catenin has the same priming
kinase as glycogen synthase (i.e. CK2), while CK1 is thought to
prime snail, DYRK isoforms may prime NRF2, JNK primes Mcl-1,ERK is proposed to prime Sp1 and Smad4, and PKA primes the
ci155 and Gli3 proteins for GSK3 mediated proteolytic processing
(Table 1). This means that the rate of ubiquitination and degrada-
tion of each of these substrates would be determined in part by the
regulation of their specific priming kinases, as well as GSK3,
although all substrates should be stabilized by the inhibition of
GSK3.
Clearly most of these proposed priming kinases are part of
dynamically regulated pathways, and thus it would seem likely
that the priming of the GSK3 substrates will also be dynamically
regulated. One obvious example of this is Mcl-1 which becomes
a GSK3 target in cells exposed to UV irradiation due to activation
of a priming event mediated by JNK [82]. Therefore, careful dissec-
tion of priming events in all of these GSK3 targets is urgently
needed, as it may be possible to moderate priming mechanisms
in order to block disease specific actions of hyperactivated GSK3,
and provides an opportunity to develop biomarkers of the priming
pathway activity. Importantly, there are already selective inhibi-
tors of some of these priming kinases that have undergone clinical
trials, and thus safety and pharmacokinetic information may
already be available (Table 2).6. Perspectives on GSK3 pathways in the development of novel
therapeutics
GSK3 has been touted as a therapeutic target ever since it was
discovered as a regulator of glucose homeostasis. Indeed several
major pharmaceutical companies developed potent and selective
small molecule chemical inhibitors which entered preclinical trials
for diabetes and dementia [1,7,115–118]. Interestingly the list of
human diseases that are associated with GSK3 dysregulation
and/or could benefit from GSK3 inhibition includes inflammation
[46], cancer [96], myocardial disease [119], Huntington’s disease
[120], Parkinson’s disease [121], kidney disease [122], psychologi-
cal stress [123], amyotrophic lateral sclerosis [124], and even
autoimmune disease [125], bacterial infection [126] and muscle
wasting [127].
The wide range of GSK3 inhibitors available for pre-clinical
studies has been comprehensively reviewed previously [128].
Interestingly, GSK3 inhibitors that have made it to clinical trials
have tended to be relatively non-specific (Table 2), and the broad
spectrum of physiological and pathophysiological roles for GSK3,
combined with the lethality of a GSK3 b knockout mouse model,
has severely restricted the development of such GSK3 inhibitors
in the clinic. The fear of wide-ranging effects is perhaps not sur-
prising, especially when scanning the huge list of GSK3 substrates
[3], or even the relatively selective range of substrates in Table 1
which appear to share the common outcome of degradation fol-
lowing GSK3 phosphorylation. The majority of these play key roles
in cell proliferation and survival, or contribute to fundamental
development. Worryingly, there are over a dozen substrates in
Table 1 where one would predict enhanced cellular proliferation
in response to GSK3 inhibition. In contrast hyperactivation of
GSK3 could reduce the production of these substrates, and that
would reduce their growth activating functions, with some poten-
tial therapeutic benefits in tumourigenesis. For example, b-catenin
is a proto-oncogene associated with a variety of common cancers
(hepatocellular, breast, colorectal, ovarian and lung). CHD1 deple-
tion suppresses cell proliferation, cell survival and tumorigenic
potential of PTEN-deficient prostate and breast cancers [65]. Sp1
is highly expressed in several cancers including colorectal and
prostate cancer and is related to poor prognosis [129]. Increased
TAZ protein is associated with human cancers, such as breast can-
cer, and TAZ protein is elevated in tumour cells with high PI3K sig-
naling, such as in PTEN mutant cancer cells. PrLr is commonly
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several neoplastic diseases, most notably in non-small cell lung
carcinoma (NSCLC) and lung squamous carcinoma. NRF2 is fre-
quently upregulated in lung cancer as a consequence of somatic
mutations in KEAP1, NFE2L2, or CUL3, and associates with increased
cell proliferation and resistance to anticancer drugs. In tumour
cells in which the KEAP1-CUL3 ubiquitin ligase is unable to repress
NRF2, stimulation of GSK3 activity has been found to suppress
NRF2, presumably by increasing ubiquitination of the CNC-bZIP
transcription factor by b-TrCP-cullin-1. In this circumstance, and
in Keap1/ mouse embryonic fibroblasts, inhibition of GSK3 by
CT99021 increases NRF2 activity [76]. This in turn is likely to fur-
ther augment cell proliferation and drug resistance. Any increase
in NRF2 signaling would provide a pro-survival effect to the
tumour by suppressing ROS levels, increasing NADPH and purine
levels, inhibiting the recruitment of immune cells and increasing
detoxification of common chemotherapeutics such as Cisplatin
and Carboplatin. Therefore, on the basis of these data one could
propose GSK3 activators rather than inhibitors as possible anti-
cancer therapeutics.
That said, GSK3 inhibition has been proposed as a potential ther-
apeutic option in specific forms of cancer [96,130,131], GSK3 activ-
ity is reported to reduce the production of at least two tumour
suppressors (Smad4 and PHLPP1 in Table 1) and there has been
at least one GSK3 inhibitor taken to clinical trial for anti-
tumourogenic potential (Table 2). There are also GSK3 substrates
whose phosphorylation by GSK3 associates with tumour develop-
ment, although this could be linked to enhanced priming, promot-
ing enhanced phosphorylation by GSK3 [132]. In addition, there are
few, if any, good examples of cell or rodent models exhibiting
robust tumour formation in response to GSK3 gene deletion.
Indeed, the GSK3 a KO mouse which lacks two of the four GSK3
alleles does not appear to develop tumours, although it exhibits
accelerated ageing by other markers [6]. Finally, lithium, a widely
used GSK3 inhibitor, is commonly prescribed to tens of thousands
of Bipolar disorder patients around the globe, with no reports of
increased risk of neoplastic disease [118]. These data indicate that
there is not a simple relationship between GSK3 activity and neo-
plastic disease.
What is very clear is that if one is to develop safe GSK3-based
therapeutic approaches for the clinic then it will be important to
understand more about GSK3 activity and GSK3 substrate phos-
phorylation status of the diseases being targeted. For example, is
there enhanced GSK3 activity (either globally or specific to the dis-
eased tissue), is there only a subset of GSK3 targets dysregulated,
and is any GSK3 defect related to enhanced basal GSK3 or loss of
GSK3 regulation? This information is key in order to develop
patient-based therapeutic options to interfere with GSK3 function
in a manner specific to the pathological issue.
To this end, the development of a panel of GSK3 substrate
biomarkers would permit more detailed classification of the many
‘GSK3-associated diseases’. This would normally involve the devel-
opment of robust phosphospecific antibodies to the residues on the
GSK3 targets, ideally with a companion non-phospho antibody to
provide a ratio of phosphorylated to non-phosphorylated sequence
in each case. The subject of this review (the GSK3 mediated
destruction of the target) may provide the opportunity to develop
tools to classify these diseases by measuring substrate protein
abundance, since in the case of the destruction hit-list this would
be directly related to the rate of phosphorylation. In this way a
more detailed, extended, and quantitative investigation of the
‘GSK3 destruction proteome’ has the potential to provide biomar-
ker panels for the classification of GSK3 associated disease, which
could be assessed in an antibody-based or MS-based assay. An ele-
gant in vitro expression cloning strategy in cytoplasmic extracts
from Xenopus identified 35 novel polypeptides whose expressionwas modified by LiCl, and a subset of these were also regulated
by interfering with Wnt regulation of the axin complex [18,81]. It
would be useful to extend this study to mammalian cells, under
different growth conditions, and in different disease states, poten-
tially with a more selective GSK3 inhibitor, or siRNA strategies. In
this way biomarker tools could be developed to establish the role
of GSK3 targets in the disease process, and to provide key informa-
tion on the efficacy of interventions aimed at GSK3 activity, or
which may alter GSK3 activity as part of their mechanism.
In summary, the emergence of the growing list of GSK3 sub-
strates which are labelled by ubiquitination for destruction via
the proteasome may provide some mechanistic understanding of
why GSK3 activity is linked to so many diseases. At the same time,
there may be opportunities to develop disease specific diagnostic
and prognostic biomarker arrays, and hence disease specific or
even patient specific therapeutic interventions, based on the
GSK3 substrate profile of the disease. It remains to be seen just
how large the GSK3-b-TrCP hit-list turns out to be, but it should
continue to provide important insights into how cells respond to
various stimuli to modify their protein compliment.
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